Clinical Trial Update: Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial update examining immunologic mechanisms and cross-neutralizing immunity after the CYD tetravalent dengue vaccine; trial completed and results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue
• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• CYD tetravalent dengue vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue, Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2020-02-05